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Chronic idiopathic axonal polyneuropathy (CIAP) is a term describing 
neuropathies where neurophysiology reveals axonal damage, their 
onset is insidious and shows slow or no progression of the disease over 
at least 6 months and no etiology is identified despite appropriate inves-
tigations (Zis, Sarrigiannis, Rao, Hewamadduma, & Hadjivassiliou, 2016).
Sensory symptoms are more prominent in CIAP and occur earlier 
in the course of the disease (Teunissen et al., 1997). Numbness is 
the most commonly reported presenting symptom (Teunissen et al., 
1997; Wolfe et al., 1999); however, pain can also be very prevalent 
in CIAP (Zis et al., 2016). Robust epidemiological data are lacking, 
and the reason for this is twofold. Firstly, in the majority of the avail-
able studies on CIAP, the diagnostic investigations are incomplete. 
Secondly, when reported, pain prevalence and characteristics were 
not the primary aim of such studies.
Pain can increase the global burden of the disease and might 
affect the patients quality of life (QoL; Rice, Smith, & Blyth, 2016; 
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-1h]uom7-m7bl: Chronic idiopathic axonal polyneuropathy (CIAP) is a term de-
scribing axonal neuropathies of insidious onset, with slow or no progression of the 
disease over at least 6 months and with no etiology being identified despite appropri-
ate investigations. We aimed to establish the prevalence of pain in patients with CIAP 
and investigate the impact of pain on quality of life (QoL).
;|_o7v: All consecutive patients with CIAP attending a specialist neuropathy clinic 
were invited to participate. Pain was assessed via the DN4 questionnaire and the 
bv-Ѵ-m-Ѵo];v1-Ѵ;Ő("őĺ;u-ѴѴ;uor-|_blb|-|bomv"1-Ѵ;Ő"ő-vv;7
to assess the severity of neuropathy. The SF-36 questionnaire was used to measure 
participants quality of life.
!;vѴ|v: Fifty-five patients with CIAP were recruited (63.6% male, mean age 
73.4 ± 8.7 years). Based on the DN4 questionnaire, peripheral neuropathic pain was 
present in 33 patients (60.0%). After having adjusted for age, gender and disease se-
verity pain showed significant negative correlations with the energy/fatigue domain of 
QoL (βƷƴƏĺƑƔƖķ p = 0.049), with the emotional well-being domain (βƷƴƏĺƒѵѶķ
p = 0.007) and the general health perception domain (βƷƴƏĺƒƔѵķp = 0.007).
om1Ѵvbom: Pain is very prevalent in CIAP and is associated with poorer emotional 
well-being, worse general health perception, and increased fatigue.
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tients with CIAP have worse QoL compared to the general pop-
ulation (Lindh, Tondel, Persson, & Vrethem, 2011); however, it is 
unclear if pain has an additional impact on the QoL in patients 
with CIAP.
The purpose of our cross-sectional study was to establish the 
prevalence of peripheral neuropathic pain in patients with CIAP and 
investigate the effect of pain on QoL.
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This was a cross-sectional study. Patients were recruited from a ter-
tiary specialist neuropathy clinic.
To be enrolled, the patients had to meet the following inclusion 
criteria: (a) clinical diagnosis of peripheral neuropathy (PN), con-
firmed on nerve conduction studies (NCS), (b) absence of other risk 
factors for developing PN (i.e., diabetes, vitamin deficiencies, expo-
sure to neurotoxic agents), (c) normal results on an extensive diag-
nostic work-up detailed below, (d) able to provide a written informed 
consent, and (e) not having a family history of PN.
The study protocol was approved by the local ethics committee.
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Demographic characteristics included age and gender.
All patients went through extensive investigations for possible 
causes of PN (Zis et al., 2016). The tests included full blood count, 
erythrocyte sedimentation rate, kidney function tests (i.e., urea and 
electrolytes), liver function tests, thyroid function tests, immunoglob-
ulin levels and electrophoresis, serum angiotensin converting enzyme, 
HbA1c, B12, and folate. We performed extensive immunological tests 
that included ANA, gliadin IgA and IgG, endomysial, transglutaminase, 
anti-dsDNA and ANCA antibodies, rheumatoid factor, and ENA panel. 
We also tested patients for any evidence of HCV and HIV infections. 
Finally, patients with rapidly progressing neuropathy were tested for 
any evidence of a paraneoplastic syndrome, including antineuronal 
antibodies and imaging studies (i.e., PET scan).
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All patients had detailed nerve conduction studies (NCS) that were 
performed by the same clinician on the day of the recruitment.
The following parameters were measured using Natus EMG 
equipment (Viking EDX): antidromic superficial radial sensory nerve 
action potential (SNAP), antidromic sural SNAP, antidromic superfi-
cial peroneal SNAP, orthodromic median SNAP, orthodromic ulnar 
SNAP, median compound muscle action potential (CMAP), ulnar 
CMAP, tibial CMAP, and common peroneal CMAP bilaterally. For all 
studies, temperature was above 32°C for the upper extremity and 
above 31°C for the lower extremity. The temperature was measured 
before and after each study on the dorsum of the hand and the foot. 
Frequency filters were 2 Hz (low) and 2 kHz (high) for the sensory 
studies and 3 Hz (low) to 10 kHz (high) for the motor studies. SNAPs 
were measured as peak-to-peak, whereas CMAPs were measured as 
onset-to-peak.
Based on the published normal values (Esper et al., 2005; Leis 
& Schenk, 2013) that we use in our department, all patients had 
evidence of axonal loss (attenuated sensory nerve action poten-
tials and/or compound muscle action potentials) in at least two 
nerves tested (Johnsen & Fuglsang-Frederiksen, 2000). No pa-
tients had evidence of demyelination, based on the following 
published criteria (Bergh & Piéret, 2004): (a) >150% prolongation 
of motor distal latency above the upper limit of normal values; 
(b) <70% slowing of motor conduction velocity below the lower 
limit of normal values; (c) >125% (>150% if the distal negative-peak 
CMAP amplitude was <80% of the lower limit of normal values) 
prolongation of F-wave latency above the upper limit of normal 
values; or (d) abnormal temporal dispersion (>30% negative-peak 
CMAP duration increase) in two or more nerves.
The type of axonal neuropathy for all patients was determined 
based on the NCS and electromyography (EMG). The electrophys-
iological diagnosis of symmetrical sensorimotor axonal polyneu-
ropathy was based on finding reduced distal sensory and/or motor 
amplitudes on nerve conduction studies and a distal to proximal 
gradient of re-innervation or denervation on EMG (Albers, 1993). 
Sensory neuronopathy also known as sensory ganglionopathy 
(SG) a type of pure sensory neuropathy affecting the cell bodies 
of the sensory neurones located in the dorsal root ganglia was di-
agnosed based on the published neurophysiological criteria (Zis, 
Hadjivassiliou, Sarrigiannis, Barker, & Rao, 2017). In SG, complete 
absence or asymmetry in the sensory nerve action potentials pre-
dominates (Zis, Hadjivassiliou, et al., 2017).
The severity of neuropathy was assessed by the overall limita-
|bomvm;uor-|_v1-Ѵ;Ő"őķ_b1_bv--Ѵb7-|;7v1-Ѵ;|_-|l;--
sures limitations in the everyday activities of the upper and lower 
limbs (Graham & Hughes, 2006).
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Neuropathic pain was assessed via the DN4 questionnaire 
(Bouhassira et al., 2005). DN4 is a clinician administered screening 
tool consisting of 10 yes/no items. A score of equal to or greater than 
4 is considered as diagnostic of neuropathic pain.
Pain intensity was assessed via a Visual Analogue Scale (VAS) 
ranging from 0 (no pain at all) to 10 (worst pain you can imagine). Pain 
intensity was assessed for two time points: pain at recruitment and 
maximum peripheral pain experienced during the disease course. 
mѴr-|b;m|vu;rou|bm]r-bmbm|;mvb|o=;t-Ѵ|oou]u;-|;u|_-mƓ
at any point were considered to suffer from a painful neuropathy.
The 36-Item Short Form Survey (SF-36), a self-reported mea-
sure of health status and quality of life (Sykioti et al., 2015), was 
used to determine patient health-related quality of life. SF-36 cov-
ers nine health and QoL domains. These domains include physical 
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functioning; role limitations due to physical health; role limitations 
due to emotional problems; energy/fatigue; emotional well-being; 
social functioning; pain; general health; and health change. Each 
item is measured using a Likert-type scale. Scores were converted 
and analyzed according to the marking guidelines for the SF-36, 
such that higher scores (out of a total of 100 for each domain) con-
stitute better health-related quality of life in this domain.
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A database was developed using the Statistical Package for Social 
Science (version 23.0 for Mac; SPSS). Frequencies and descriptive 
statistics were examined for each variable. Comparisons between 
patients with painful CIAP and patients with painless CIAP were 
made using Students t tests for normally distributed continuous 
data, MannWhitneys U test for non-normally distributed, and chi-
square test or Fishers exact test for categorical data.
Where differences with a p value of lower than 0.10 were found, 
these variables were entered into linear regression models, with the 
QoL domain score being the dependent variable. All accuracy and 
generalization assumptions for the model were checked.
The level of statistical significance was set at the 0.05 level.
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Fifty-five patients with CIAP were recruited (63.6% male, mean age 
73.4 ± 8.7 years). Forty-seven patients (85.5%) had a symmetrical 
length-dependent sensorimotor axonal PN, and eight (14.5%) had a 
sensory ganglionopathy. Mean age at neuropathic symptoms onset 
-vѵƒĺƐƼƐƐƏĺƔ;-uvŐu-m]bm]=uolƑƔ|oѶƔ;-uvőĺ;u-ѴѴ"
scores ranged from 1 to 7 (mean 3.3 ± 1.6).
Eleven patients (20%) reported pain to be the first symptoms of 
the PN (six reported a sharp pain, two reported allodynia, and three 
reported a burning painful sensation).
Based on the DN4 questionnaire, and a VAS score of at least 
4/10, neuropathic pain at any point was present in 33 patients 
(60.0%). Based on a VAS score of at least 4/10, pain was present on 
examination in 20 patients (36.4%), whereas the other 13 patients 
reported spontaneous neuropathic pain, occurring randomly during 
the day. The pain intensity on examination ranged from 0 to 10 
(mean 4.1 ± 2.9), when the maximum pain experienced ranged from 
5 to 10 (mean 8.6 ± 1.6).
None of the 22 patients reporting no pain were on anti-neuralgic 
treatment.
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Table 1 summarizes the demographic and the clinical characteristics 
of the patients with painful and the patients with painless CIAP. The 
two groups did not differ significantly regarding age, gender, type of 
neuropathy, or disease duration. Patients with painful neuropathy 
had a more severe neuropathy compared to patients without pain 
Ől;-m"o;u-ѴѴv1ou;ƒĺƕƼƐĺƔvĺƑĺѶƼƐĺƔķp = 0.024).
As shown in Table 1, apart from the domain of pain, patients with 
painful CIAP presented with significantly worse scores compared to 
patients with painless CIAP in the following quality of life modali-
ties: physical functioning (p = 0.002), role limitations due to physical 
health (p = 0.009), energy/fatigue (p = 0.007), emotional well-being 
(p = 0.001), general health (p = 0.002), and health change (p = 0.019), 
whereas there was a trend of statistically significant difference in 
the domain of social functioning (p = 0.056).
ƒĺƒՊ|ՊѴ|b-ub-|;-m-Ѵvbv
Table 2 summarizes the multivariate linear regression models for all 
QoL domains, which showed statistically significant differences or 
a trend for a statistical significant difference. After having adjusted 
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Demographics
Age, in years (SD) 73.5 (6.7) 73.3 (11.2) 0.910
Male gender (%) 19 (57.6) 14 (63.6) 0.252
Clinical characteristics
Disease duration, in 
years (SD)
9.7 (7.5) 11.3 (7.1) 0.440
Type of neuropathy 0.876
Symmetrical 
length-dependent 
PN (%)
28 (84.8) 19 (86.4)
Sensory ganglionop-
athy (%)
5 (15.2) 3 (13.6)
Neuropathy severity
"ulv1ou;
(SD)
1.5 (0.8) 0.9 (0.9) 0.015
";]v1ou;ŐSD) 2.3 (1.0) 1.9 (1.2) 0.221
$o|-Ѵ"v1ou;
(SD)
3.7 (1.5) 2.8 (1.5) 0.024
Quality of life modalities
Physical functioning 36.4 (21.7) 58.6 (29.2) 0.002
Role limitations due to 
physical health
34.3 (23.8) 55.1 (33.6) 0.009
Role limitations due to 
emotional problems
66.9 (31.6) 80.7 (31.4) 0.118
Energy/Fatigue 35.6 (20.2) 50.9 (18.7) 0.007
Emotional well-being 59.7 (23.2) 78.4 (14.0) 0.001
Social functioning 56.1 (32.0) 72.7 (29.3) 0.056
Pain 37.4 (21.5) 72.2 (24.4) <0.001
General health 41.1 (22.7) 58.9 (15.4) 0.002
Health change 32.6 (18.2) 43.2 (11.4) 0.019
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significant negative correlations with energy/fatigue domain 
(βƷƴƏĺƑƔƖķp = 0.049), emotional well-being (βƷƴƏĺƒѵѶķp = 0.007), 
and general health perception (βƷƴƏĺƒƔѵķp = 0.007).
ƓՊ |Պ	"&""
This cross-sectional study demonstrates that three out of five pa-
tients with CIAP suffer from peripheral neuropathic pain secondary 
to their neuropathy. Very importantly, presence of pain is correlated 
with worse quality of life in the energy/fatigue domain, the emo-
tional well-being domain, and the general health perception domain.
Contrary to the common misperception that painful neurop-
athies are related to diabetes, our study strengthens the evidence 
that neuropathies of etiologies other than diabetes can be equally 
painful. The reported prevalence of pain in patients with diabetic 
PN, confirmed with NCS, is estimated to be 40%50% (Ware, 1992). 
Previous systematic reviews have established that the prevalence 
of pain in paraneoplastic neuropathies is 58% (Didangelos, Doupis, 
& Veves, 2014) and in platin-induced neuropathies is 46%, when 
referring to patients with established PN following chemotherapy 
completion (Zis, Paladini, et al., 2017). These figures are very similar 
to our findings, as in our cohort of CIAP patients, the estimated prev-
alence of peripheral neuropathic pain was 60%.
In 2010, Erdmann et al. described a case series of ninety-one 
patients with CIAP and they reported that the overall prevalence 
of pain in CIAP is 69% (Brozou, Vadalouca, & Zis, 2017). However, 
when looking more specifically into the peripheral neuropathic pain, 
the reported prevalence dropped to 42% (Brozou et al., 2017). There 
are few possible explanations for the difference between the latter 
figure and the prevalence in our cohort.
Firstly, the mean age of our CIAP population was approximately 
7 years higher compared to Edmanns cohort and pain has been 
shown to increase with age (Erdmann et al., 2010). Secondly, con-
trary to our study, Erdmann et al. provided no information about the 
clinical severity of the PN and therefore the reported prevalence 
may also vary because of the different PN severity of the two co-
horts. In our study population, patients with pain had a more se-
;u;ķ -v |_bv-v7;|;ulbm;70 |_;"ĺ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of pain varies among individuals and depends on many variables, 
including genetic predisposition and gender (Fayaz, Croft, Langford, 
Donaldson, & Jones, 2016; McGrath, 1994).
A novelty of our study is that our cohort included patients with 
idiopathic sensory ganglionopathy, the second commonest type of 
axonal neuropathy. In total, one out of seven CIAP patients (14.5%) 
had a sensory ganglionopathy, rather than a symmetrical length-de-
pendent neuropathy, whereas in Edmanns cohort all patients had 
a symmetrical sensorimotor neuropathy. The univariate analysis 
showed that presence of pain does not depend on the neurophys-
iological type of CIAP.
In this study, we also described the QoL of patients with CIAP. 
In the univariate analysis, we found that patients with pain have sig-
nificantly worse scores on all QoL domains apart from the domain $
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of role limitations due to emotional problems (not statistically sig-
nificant) and the domain of social functioning (trend for statistical 
significance). This observation differs to what has been reported by 
Erdmann et al. who found only significant correlations between pain 
and the physical functioning domain (Brozou et al., 2017). Again, the 
demographic and clinical differences between the two cohorts may 
account for this difference.
Another novelty of our study is that we performed multivariate 
analyses and were able to identify correlations between pain and the 
QoL domains after having adjusting for age, gender, and PN severity. 
The domains where pain plays independently a significant role are 
the energy/fatigue, the emotional well-being, and the general health 
perception domains. This is particularly important as it highlights 
that pain plays a significant role in the emotional state of the patient 
and might cause or enhance feelings of anxiety and depression, re-
gardless of age, gender, and disease severity (Zis, Daskalaki, et al., 
2017). Therefore, questioning about the presence of pain in CIAP 
patients is crucial as by symptomatic treatment of pain the QoL of 
patients might improve. A future prospective study comparing pa-
tients on symptomatic treatment with those not on any treatment 
may be able to confirm this.
Treatment of PN depends on the etiology and primarily aims 
to stop the disease progression. As CIAP is by definition of un-
known etiology, management of CIAP targets to symptomatically 
relieve the symptoms that patients experience. With regards to 
neuropathic pain, no completed studies for the evaluation of the 
effectiveness of various anti-neuralgics in the treatment of CIAP 
exist. Patient Assisted Intervention for Neuropathy: Comparison 
o= $u;-|l;m| bm !;-Ѵ b=; "b|-|bomv ŐŊ$!o"ő bv -
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dress this particular question; the results of this study (registra-
tion NCT02260388) are expected to be available in late 2018. 
Therefore, until then, the management of pain in CIAP should be 
based on the published guidelines for the management of neuro-
pathic pain (Vadalouca et al., 2012).
uu;vѴ|vv_oѴ70;bm|;uru;|;7b|_vol;1-|bomķ_o;;uķ
given the limitations of our design. This is a cross-sectional obser-
vational study comparing CIAP patients with and without peripheral 
neuropathic pain based on patients attending a specialized clinic, 
and the results may not be generalizable to other settings. For ex-
-lrѴ;ķ bm ou v|7ķ ; v;7 |_;" |o 7;|;ulbm; |_; 1Ѵbmb1-Ѵ
severity of the neuropathy, whereas other departments use other 
scales. The independent role of pain in the overall QoL might differ if 
other tools are used, something that could be investigated in a future 
study. Furthermore, our cohort included patients with large fiber ax-
onal peripheral neuropathies only. Idiopathic small fiber neuropathy 
is another area that merits further consideration, as it is a particu-
larly painful condition. Finally, we were able to demonstrate that the 
presence of pain is an independent determinant of QoL after having 
adjusted for age, gender, and neuropathy clinical severity as this was 
-vv;vv;7b-|_;"ĺ$_;Ѵ-||;u;-Ѵ-|;v=bm;lo;l;m|vo=|_;
upper limbs and gait. Thus, primarily, it depends on the motor in-
volvement secondary to neuropathy or can be abnormal in cases of 
severe sensory ataxia leading to gait impairment. Therefore, we have 
not adjusted for the presence of other sensory symptoms such as 
itchiness and tingling, though in our clinical practice patients rarely 
complain about how other sensory symptoms than pain affect their 
lives.
In conclusion, pain is very prevalent in CIAP and significantly 
blr-1|vom oĺr|blll-m-];l;m|o=r-bm bm v1_r-|b;m|v
might prove beneficial in improving QoL. Future prospective stud-
ies are needed to explore further the relationship between pain 
and QoL.
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